Enliven Therapeutics, Inc.
ELVN
Positions held
Your positionsELVN isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Enliven Therapeutics operates in the biotechnology sector, focusing on innovative therapies that address unmet medical needs, which positions it well for future growth as the industry evolves.
- The company has a market cap of approximately $3.11 billion, indicating significant investor interest and potential for future capital appreciation.
- Despite current challenges, analysts have a strong buy recommendation, with a target mean price of $73.67, suggesting substantial upside potential.
- Enliven Therapeutics has reported zero revenue for multiple quarters, indicating a lack of commercial success and potential viability concerns.
- The company has consistently posted negative net income, with a total of -103.69 million in 2025, reflecting ongoing financial struggles.
- Current financial indicators show a strong sell signal with a score of -16.00, highlighting bearish market sentiment and technical weaknesses.
Fundamentals
| Market cap | $2.98B | Enterprise value | $2.08B | Trailing P/E | — | Forward P/E | -17.26 |
| PEG | — | Price / book | 3.32 | Beta | 0.34 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -15.3% | ROA | -11.0% | Debt / equity | 0.00 |
| Current ratio | 64.07 | Free cash flow | -$45.26M | Analyst recommendation | strong_buy | Mean target | $73.67 |
| 52w high | $62.32 | 52w low | $14.79 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$32.5M | -$23.6M | -$29.7M | -$20.1M | -$25.3M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$37.2M | -$27.8M | -$34.3M | -$25.1M | -$28.6M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — |
| Net income | -$104M | -$89.0M | -$71.6M | -$37.7M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$120M | -$105M | -$83.5M | -$38.8M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-07 · Halozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trial
2026-10-07 · Enliven Therapeutics Reaches Realignment With FDA on Final Design of Relcobatinib's Phase 3 Trial
2026-10-02 · Morgan Stanley Initiates Enliven Therapeutics at Overweight
2026-10-01 · JPMorgan Initiates Enliven Therapeutics at Overweight With $75 Price Target
2026-09-21 · Enliven Therapeutics Insider Sold Shares Worth $251,754, According to a Recent SEC Filing
2026-09-21 · Enliven Therapeutics Insider Sold Shares Worth $303,003, According to a Recent SEC Filing
2026-09-03 · Enliven Therapeutics to Present at Upcoming Investor Conferences
2026-09-02 · Miners And More Lead Slew Of Stocks To Watch — With This Line In Focus
2026-08-18 · William Blair Initiates Enliven Therapeutics at Outperform
2026-08-18 · Mizuho Raises Price Target on Enliven Therapeutics to $73 From $62, Keeps Outperform Rating
Price (daily)
Full chart · RSI · MACD · patterns